NCT05945823: An ongoing trial by Taiho Oncology, Inc.
This trial is ongoing. It must report results 11 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05945823 |
|---|---|
| Title | A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 13, 2023 |
| Completion date | March 31, 2026 |
| Required reporting date | March 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |